More ROR1s enter the clinic
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Ivonescimab takes on pancreatic cancer
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
No holding back Claudin
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Genor goes one better
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
